Search Results - "Fujii, Hideki"

Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L.

Authors: Kawanaka, Miwa Fujii, Hideki Iwaki, Michihiro et al.

Source: Diagnostics (2075-4418). Jul2025, Vol. 15 Issue 13, p1591. 10p.

Novel evaluation of bone reaction/growth around full hydroxyapatite-coated stem using digital tomosynthesis imaging: confirmation of very early bone growth around the stem.

Authors: Fujii, Hideki Hayama, Tetsuo Amagami, Ayano et al.

Source: BMC Musculoskeletal Disorders. 10/17/2025, Vol. 26 Issue 1, p1-8. 8p.

Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease.

Authors: Fujii, Hideki Fujii, Makoto Iwaki, Michihiro et al.

Source: Hepatology Research. May2023, Vol. 53 Issue 5, p391-400. 10p.

Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease.

Authors: Nouso, Kazuhiro Kawanaka, Miwa Fujii, Hideki et al.

Source: Hepatology Research. Oct2024, Vol. 54 Issue 10, p912-920. 9p.

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large‐scale multicenter retrospective study.

Authors: Fujii, Hideki Suzuki, Yuichiro Sawada, Koji et al.

Source: Hepatology Research. Nov2023, Vol. 53 Issue 11, p1059-1072. 14p.

Extremely Rapid Age Hardening in Ti-5Al-2Fe-3Mo Solution Treated at High α + β Temperature Region.

Authors: Kunieda, Tomonori Kohigashi, Yusuke Fujii, Hideki et al.

Source: Metallurgical & Materials Transactions. Part A; Oct2021, Vol. 52 Issue 10, p4424-4437, 14p

Precipitation Behaviors in Ti–2.3 Wt Pct Cu Alloy During Isothermal and Two-Step Aging.

Authors: Akamine, Hiroshi Mitsuhara, Masatoshi Nishida, Minoru et al.

Source: Metallurgical & Materials Transactions. Part A; Jul2021, Vol. 52 Issue 7, p2760-2772, 13p

Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan.

Authors: Tsutsumi, Tsubasa Kawaguchi, Takumi Fujii, Hideki et al.

Source: Alimentary Pharmacology & Therapeutics. Jun2024, Vol. 59 Issue 12, p1559-1570. 12p.

Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group.

Authors: Tsuji, Keiji Tamaki, Nobuharu Kurosaki, Masayuki et al.

Source: Hepatology Research. May2025, Vol. 55 Issue 5, p675-684. 10p.

Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study.

Authors: Fujii, Hideki Doi, Haruna Ko, Tetsuhisa et al.

Source: BMC Gastroenterology. 7/10/2020, Vol. 20 Issue 1, p1-9. 9p. 1 Diagram, 2 Charts, 1 Graph.

12-Hydroxyheptadecatrienoic Acid Predicts Hepatocellular Carcinoma Development During Nucleos(t)ide Analogue Therapy.

Authors: Ikenaga, Hiroko Kozuka, Ritsuzo Inoue, Kirara et al.

Source: Cancers. Feb2026, Vol. 18 Issue 4, p542. 16p.

Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy.

Authors: Tada, Toshifumi Kurosaki, Masayuki Toyoda, Hidenori et al.

Source: Liver International. Nov2024, Vol. 44 Issue 11, p3060-3071. 12p.

Primary pulmonary artery sarcoma treated with simultaneous pulmonary valve replacement, artificial vessel replacement, and total right pneumonectomy: a case report.

Authors: Fujii, Kento Morita, Hideki Nagano, Hiroshi et al.

Source: General Thoracic & Cardiovascular Surgery Cases. 8/27/2025, Vol. 4 Issue 1, p1-7. 7p.

Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction–associated fatty liver disease.

Authors: Fujii, Hideki Nakamura, Naotoshi Fukumoto, Shinya et al.

Source: Liver International. May2022, Vol. 42 Issue 5, p995-1004. 10p. 1 Diagram, 5 Charts.

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases.

Authors: Fujii, Hideki Fukumoto, Shinya Enomoto, Masaru et al.

Source: Scientific Reports. 7/5/2021, Vol. 11 Issue 1, p1-9. 9p.

This result is not displayed to guests.
Login for full access.

Total Hip Arthroplasty for Crowe III/IV Hip Dysplasia With Oblique Subtrochanteric Shortening Osteotomy and S‐ROM‐A Modular Stem: 10‐Year Outcomes.

Authors: Hayama, Tetsuo Takahashi, Motoi Otani, Takuya et al.

Source: Orthopaedic Surgery. Oct2025, Vol. 17 Issue 10, p2895-2902. 8p.

Utilizing Altmetrics to Track Advancements in Noninvasive Tests for MASLD.

Authors: Yoneda, Masato Sumida, Yoshio Kamada, Yoshihiro et al.

Source: Hepatology Research. Oct2025, Vol. 55 Issue 10, p1404-1409. 6p.

Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib.

Authors: Saito, Kei Fujii, Hideki Kono, Keiji et al.

Source: Clinical Kidney Journal. Jan2021, Vol. 14, p325-331. 7p.

Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group

Authors: Mashiba, Toshie Joko, Kouji Kurosaki, Masayuki et al.

Source: Journal of Viral Hepatitis. Jul2022, Vol. 29 Issue 7, p551-558. 8p.